They are good without being exceptional, which is what some were hoping for.
Reality is that if the primary endpoint was met, a partnership would be on the cards.
As it wasn't- it's a wait and see proposition and hopefully the full phase 2 results show the treatment beating placebo, or else it's a dead program.
That's the reason why people have jumped ship, the risk profile is higher now compared to looking at NASH through the lens of a phase 1 trial on very small populations.
Goodluck!
IMC passes NASH interim analysis, page-19
-
- There are more pages in this discussion • 15 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
9.9¢ |
Change
0.000(0.00%) |
Mkt cap ! $22.57M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 114250 | 9.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 9.6¢ | 556 | 1 |
View Market Depth
| Last trade - 16.12pm 12/09/2024 (20 minute delay) ? |
| IMC (ASX) Chart |
Day chart unavailable